Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H37N5O5S |
Molecular Weight | 579.71 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(C)C1=NC2=CC=C(C=C2O1)C(=O)N(CC(C)C)C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4
InChI
InChIKey=RGTBBKSFLZZHLT-IZZNHLLZSA-N
InChI=1S/C30H37N5O5S/c1-5-34(4)29-32-24-12-11-22(14-27(24)40-29)28(37)35(16-20(2)3)17-26(36)25(13-21-9-7-6-8-10-21)33-30(38)39-18-23-15-31-19-41-23/h6-12,14-15,19-20,25-26,36H,5,13,16-18H2,1-4H3,(H,33,38)/t25-,26+/m0/s1
Molecular Formula | C30H37N5O5S |
Molecular Weight | 579.71 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:37:34 GMT 2023
by
admin
on
Sat Dec 16 11:37:34 GMT 2023
|
Record UNII |
QJ6KY7R5SS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
42609861
Created by
admin on Sat Dec 16 11:37:35 GMT 2023 , Edited by admin on Sat Dec 16 11:37:35 GMT 2023
|
PRIMARY | |||
|
QJ6KY7R5SS
Created by
admin on Sat Dec 16 11:37:35 GMT 2023 , Edited by admin on Sat Dec 16 11:37:35 GMT 2023
|
PRIMARY | |||
|
1160489-55-3
Created by
admin on Sat Dec 16 11:37:35 GMT 2023 , Edited by admin on Sat Dec 16 11:37:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
PHARMAKINETIC ENHANCER
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
TMC-558445 manufactured by Tibotec pharmaceuticals is currently being tested in a phase-I study. Results are not available yet. At CROI in February 2009, new pharmacoenhancers were introduced for the first time that could challenge ritonavirs booster monopoly. The advantages of these new agents inhibiting the CYP3A system is that they have no antiviral effect and thus cannot cause resistance. Obviously, there are no reports yet about long-term side effects and the effects of such a total inhibition of enzyme systems.
|